13 withdrawn. 13 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 13 | Withdrawn 13 |
Follow Demyelinating Diseases: new trials by email Literature Review of Demyelinating Diseases trials Research Report on Demyelinating Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testosterone Treatment for Erectile Dysfunction and Multiple Sclerosis XYOSTED 75 milligram (mg) in 0.5 ML Auto-Injector - Multiple Sclerosis, Erectile Dysfunction | Phase 4 | Withdrawn | Tulane University | 2026-06-01 | 2026-10-02 | |
| Assessing the Cognitive Benefits of Ozanimod and Their Brain-Biomarkers in MS Ozanimod - Multiple Sclerosis | Phase 4 | Withdrawn | The University of Texas at Dallas | 2024-06-01 | 2024-08-09 | |
| A Study To Determine The Effect Of Ocrelizumab On Leptomeningeal Inflammation In Multiple Sclerosis Ocrelizumab - Multiple Sclerosis | Phase 4 | Withdrawn | Hoffmann-La Roche | 2023-09-15 | 2024-01-23 | |
| Mechanisms of Action of Dimethyl Fumarate (Tecfidera) in Relapsing MS Dimethyl Fumarate - Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting | Phase 4 | Withdrawn | Washington University School of Medicine | 2016-04-01 | 2016-07-20 | |
| Brimonidine Tartrate for the Treatment of Injection Related Erythema peginterferon beta-1a, brimonidine tartrate, Vehicle Gel - Relapsing-Remitting Multiple Sclerosis (RRMS) | Phase 4 | Withdrawn | Biogen | 2016-02-01 | 2016-04-25 | |
| Study to Explore the Onset of Efficacy on Magnetic Resonance Disease Activity of BG00012 (Dimethyl Fumarate) in Patients With Relapsing remitTing Multiple Sclerosis dimethyl fumarate, Placebo - Relapsing Remitting Multiple Sclerosis | Phase 4 | Withdrawn | Biogen | 2015-07-01 | 2015-12-28 | |
| Study to Evaluate Fatigue in Participants With Relapsing Remitting Multiple Sclerosis When Treated With Dimethyl Fumarate dimethyl fumarate - Relapsing-Remitting Multiple Sclerosis, Multiple Sclerosis | Phase 4 | Withdrawn | Biogen | 2015-06-01 | 2015-09-07 | |
| Effect of an Individualized Patient Support Program on Treatment Satisfaction in Fingolimod-treated Patients With RRMS individualized patient support program, Standard care - Relapsing-remitting Multiple Sclerosis | Phase 4 | Withdrawn | Novartis Pharmaceuticals | 2013-07-01 | 2014-09-30 | |
| ENGYNE Exploring Gilenya in Patients With Neutralizing Antibodies Against Interferon Fingolimod - Multiple Sclerosis | Phase 4 | Withdrawn | Novartis Pharmaceuticals | 2013-06-01 | 2017-04-20 | |
| The Effects of Ethyl-Alpha-Guanido-Methyl Ethanoate on Skin Reactions From Glatiramer Acetate Injections AGEE cream, 1% Steroid Cream, topical placebo cream with no active ingredients - Multiple Sclerosis | Phase 4 | Withdrawn | University of Nebraska | 2010-02-01 | 2023-08-23 | |
| A Proof-of-Concept Study to Correlate Retinal Nerve Fiber Layer Changes in Patients With Multiple Sclerosis Treated With Natalizumab or Interferon Beta 1-a TYSABRI and AVONEX - Relapsing-remitting Multiple Sclerosis | Phase 4 | Withdrawn | Biogen | 2008-11-01 | 2024-06-03 | |
| Implementation Study of Treatment Optimization Recommendations on Relapsing-Remitting Multiple Sclerosis (RR MS) Subjects Rebif - Relapsing-Remitting Multiple Sclerosis | Phase 4 | Withdrawn | EMD Serono | 2004-11-01 | 2013-08-06 | |
| Induction Therapy With a Single High Dose Bolus of Intravenous Methotrexate With Leucovorin Rescue, Prior to Initiation of AVONEX® Treatment, in Patients Presenting With a First Acute Demyelinating Event. interferon beta 1a, methotrexate, methylprednisolone - Demyelinating Disorders, Multiple Sclerosis | Phase 4 | Withdrawn | MidAmerica Neuroscience Research Foundation at Rowe Neurology Institute | 2002-05-01 | 2018-04-12 |
Multiple Sclerosis (8) · Multiple Sclerosis, Relapsing-Remitting (7) · Erectile Dysfunction (1) · Erythema (1) · Injection Site Reaction (1) · Myelitis (1) · Neuritis (1) · Optic Neuritis (1)
Autoimmune Diseases (13) · Autoimmune Diseases of the Nervous System (13) · Demyelinating Autoimmune Diseases, CNS (13) · Immune System Diseases (13) · Nervous System Diseases (13) · Multiple Sclerosis (5) · Central Nervous System Diseases (1) · Central Nervous System Infections (1) · Chemically-Induced Disorders (1) · Cranial Nerve Diseases (1) · Drug-Related Side Effects and Adverse Reactions (1) · Extravasation of Diagnostic and Therapeutic Materials (1) · Eye Diseases (1) · Genital Diseases (1)
Dimethyl Fumarate (3) · Interferon beta-1a (3) · Brimonidine Tartrate (1) · Drugs, Generic (1) · Fingolimod Hydrochloride (1) · Methotrexate (1) · Methylprednisolone (1) · Natalizumab (1) · Standard of Care (1) · ocrelizumab (1) · ozanimod (1) · peginterferon beta-1a (1)
Biogen (4) · Novartis Pharmaceuticals (2) · EMD Serono (1) · Hoffmann-La Roche (1) · MidAmerica Neuroscience Research Foundation at Rowe Neurology Institute (1) · The University of Texas at Dallas (1) · Tulane University (1) · University of Nebraska (1) · Washington University School of Medicine (1)
United States (4) · Russia (1)
Anne Cross, MD (1) · Bart Rypma, PhD (1) · Laura Piccio, MD (1) · Mary Filipi, PhD, APRN (1) · Omar A Raheem, MD (1)
2015 (1)